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South Africa’s laws with regard to human biological material 
(HBM), specific to that of genetic research, have over the 
years proved to be a fairly prominent topic of discussion. This 
in turn has led to the drafting and now enacted legislation, 
chapter eight of the National Health Act (NHA). However, 
several questions have arisen, post promulgation, with regard to the issue 
of ownership of such biological materials. One of the major issues identified 
is lack of a clear enough definition of HBM. Various acts and regulations 
related to research and the diagnostic use of HBM define such materials 
in various ways. The lack of a universal definition therefore creates room in 
the legislature from which exploitative acts may arise.  This article aims to 
highlight some of these gaps as well as put forward recommendations for a 
universal definition to be used by all involved with HBM.
Defining ownership
The description of ownership stems mainly from South African 
common-law.[1] Ownership has been defined in various decisions as 
‘the most complete real right which gives the owner the most complete 
and absolute entitlement to a thing. Even so, it is a right which can be 
limited by objective law and by the rights of others’. A ‘thing’ is defined 
‘in terms of characteristics, as a corporeal or tangible object external 
to persons and which is, as an independent entity, subject to judicial 
control by a legal subject, to whom it is useful and of value’.[1]
HBM such as genetic material (DNA and RNA) in this sense is 
reflective of what a ‘thing’ would be. Genetic material meets the 
criteria that are used as definable characteristics of a thing. It is 
corporeal, in belonging to a physical body and tangible, in being 
material that can be made visible, of definite substance and can be 
quantified.[1]
According to Regulation 180(S26) in chapter eight of the NHA, an 
exclusive right in human tissue is acquired by any person who obtains 
the human tissue, subject to informed consent and the provisions and 
restrictions of the NHA or any other law.[2] Such regulation pertaining to 
biological material capable of yielding genetic material within the NHA 
portrays a sense of exclusive property rights from donor to donee, the 
latter being a researcher, doctor, or research institute, for example.[3] 
This transfer of exclusive rights therefore implies that when elements of 
the human body are separated from a person, the material gained loses 
its identity and is to be considered a biological material that no longer 
has relatedness to the person who has donated it. This may be true for 
biological material removed from a person when the sample is coded or 
made anonymous but the genetic information within those materials 
are capable of identification. For example, if a population group under 
genetic investigation is found to hold in their genomic sequence a 
rare variant or Single Nucleotide Polymorphism (SNP) that specifically 
clusters within that group, it then acts as an identifiable marker to that 
population. Depending on the type of genetic association predicted to 
be linked to that SNP, a population may become vulnerable to further 
genetic exploitation and cultural intrusion. Therefore, while national 
regulations exhibit  exclusive rights  in biological and genetic materials 
as a property that can be transferred from one person to another, subject 
to certain restrictions, the intimate nature of genetic material begs the 
question of: To whom does such material truly belong?
Redefining ownership for human 
biological material
Redefining ownership in respect of materials obtained from human 
beings proves to be a formidable task as various aspects need to be 
taken into consideration. The question to be considered in redefining 
the concept of ownership within current legal understanding is 
described as follows: How do we develop a legal definition for 
ownership of HBM without making humanity appear as a commodity 
or without loss of human dignity? The legal definition of HBM and 
tissue as they stand is poorly defined, with variations occurring in 
different segments of legislation related to human bodily materials[4] 
such as tissue, blood and blood products. 
HBM removed from a human being either living or deceased should 
be entitled to the rights attributed to the body as a whole. Under these 
conditions I propose the following definition: A human biological 
sample shall include all cell types capable of being removed, by a trained 
professional, from a human body either intravenously and/or surgically 
without causing serious harm to a living individual provided informed 
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consent has been granted prior to the removal. The cell types should 
be classified based on the cell potency, which is defined as a cell’s ability 
to differentiate into one or more cell types within an organism[5] from 
which these specific cell types form, that is, totipotency, pluripotency, 
multipotency, oligopotency and unipotency. In this way, all cell types are 
covered, from stem cells and blood and blood products to all forms of 
tissue which can be defined as a set of specialised cells that aggregate 
together to perform a specific function as a single unit.[6]
A totipotent cell is a stem cell capable of becoming any cell in the 
body. They are usually produced during the first few cell divisions of 
embryogenesis. It is from these stem cells that all other stems cell form.[5] 
From these cells another set of stem cells are formed, known as pluripotent 
stem cells. These cells have the potential to differentiate into nearly all cells 
within the body but are sectionalised based on which of the three germ 
layers[5] they enter into. Pluripotent stem cells have self-renewal properties 
as well as the potential to form all cell types of an adult organism.[7]
Multipotent stem cells are the next set of stem cells to form 
following a cascade of cell differentiation towards unipotent cells. 
These cells are capable of differentiation in various cell types but only 
with a certain family.[5] They are therefore limited in the cell types they 
can become. For example, the bone marrow contains multipotent 
stem cells that give rise to all the cells of the blood but not to other 
types of cells. Adult haematopoeitic stem cells are multipotent.[8] 
Oligopotent stem cells can differentiate into only a few cells within 
a cell type family, such as lymphoid or myeloid stem cells. The corneal 
epithelium is a squamous epithelium that is constantly renewing and 
is oligopotent.[8]
Lastly, unipotent cells are only able to produce one type of cell, their 
own, but still maintain the property of self-renewal, which distinguishes 
them from non-stem cells. Most epithelial tissues self-renew throughout 
adult life due to the presence of unipotent progenitor cells.[5,9]
Serious harm as adapted from the Unites States Code can be defined as 
any form of protracted or obvious loss of impairment of the function of a 
bodily member, organ or mental faculty (physical and/or mental disability), 
protracted or obvious disfigurement, extreme physical pain or risk of 
death that can occur during the extraction of cellular material from a living 
human host body.[10] For example, the unintended awakening, of a patient 
during an extraction of cellular material by surgical procedures from their 
body, due to the administration of an insufficient amount of anaesthesia. 
The effect of such an event could result in the patient experiencing 
extreme pain as well as many other unintended consequences including 
the risk of death should the patient react in a manner that endangers his 
or her life due to the level of pain experienced. 
Genomics and gene patents 
Prior to the recent international ownership issues relating to genetic 
material such as that of patent laws, the common understanding was that 
such material was an open source with no one having exclusive rights to 
ownership over any piece of it. This allowed all countries to share their 
genetic resources freely.[11] An example of open source in genetics is the 
Human Genome Project, an endeavour that required the collaboration 
of a number of different institutes sharing their information and data, 
therefore forcing each of them to decide on flexible research standards.
The realisation that both scientific and commercial gains can be made 
from human biological material has led to more stringent control over 
such materials nationally. Safrin[11] refers to this as the ‘legal enclosure of 
genetic material’, which she attributes to two developments: 
• the patenting of genetic material by predominantly developed 
countries 
• a response to the privatisation of genes through the patent 
system and the extension of sovereignty over genetic resources by 
developing countries. 
This patent action has led to a reaction by many in the developing 
world, implementing state sovereign rights or a form of national 
control over genetic resources. The interaction between the patent 
system and the sovereign-based system is described by Safrin as a 
‘corrosive interplay’ eventually leading to a system she describes as 
‘hyperownership’ of genetic material to the anticommons trap.
The anticommons is a concept introduced by Micheal Heller[12] as 
‘the mirror image of common property’ which plays in contrast to 
Hardin’s Tragedy of the Commons.[13] The philosophical idea expressed 
by Hardin sets forth the consequences of overuse of a natural 
resource, such that access to that resource becomes overrun. The 
anticommons however, proposes the opposite: a tragedy is likely to 
arise ‘when these individuals or entities employ their rights to veto 
the use of a given resource and in so doing waste the resource by it’s 
under consumption compared with the social optimum’.[12]
Hardin’s Tragedy of the Commons represents over-consumption and 
exploitation of a resource without giving back to the entity from which it was 
taken. Heller’s anticommons approach aims to identify the lack of willingness 
to allow others access and share in the benefits of that resource. From a 
genomics point of view this represents the effects of ‘safari or helicopter’ 
research, whereby genomic samples were collected from communities 
without proper consent or fair compensation, consequently leading to 
many nations seeking sovereign mandates over their genetic materials. In 
either case the action of both these groups incurs both social and economic 
repercussions. Additionally, the development of excessive sovereign control 
or ownership of genetic material is likely to lead to over-regulation,[11] with 
bureaucratic red tape impeding important genetic research. 
Although UNESCO’s declaration states that the human genome in 
its natural state should not give rise to financial gain,[13] it does not 
offer any protection over segments of the human genome. Many 
developed countries allow for genes that have been isolated, extracted 
and functions determined, to become a commodity, gain commercial 
value and allow for their patenting.[11,12] In South Africa, current laws, 
such as the Biodiversity Act,[14] restrict access to genetic material for the 
purpose of acquiring remuneration but the exclusion of human genetic 
material from the Act once again leaves a gap for exploitative means.
Globally, many developing countries such as Mexico, Brazil and India 
for example have in place regulatory guidelines[15] that view human 
genetic material as a natural resource based on the concept of Genomic 
Sovereignty described as ‘the capacity of a people, country or nation to 
own, to control both access and use of samples, data and knowledge 
emanating from genetic material’.[16] With the awakening of the wealth 
of genetic data available in their respective countries the so-called 
traditional distinctions in legal understanding between human and 
non-human genetic resources is slowly being eroded, with international 
bodies calling for amendments to the Convention of Biological Diversity 
to be made that govern access to human genetic material as well.[1]
Patenting of DNA in biotechnology
South Africa is fairly silent with regard to patenting any form of human 
genetic material and has in place laws, regulations and guidelines such 
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as the Biodiversity Act as well as the guidelines for South Africa’s bio-
prospecting, access and benefit-sharing regulatory framework issued 
by the Department of Environmental Affairs.[17] Within these laws, 
issues surrounding patenting of biological resources are mentioned 
but indicate that these laws and guidelines exclude human genetic 
material. Nonetheless extrapolation of relevant information from 
such legal documents is still relevant in relation to human genetic 
material and could therefore be used as a stepping stone in an effort 
to set in motion regulatory legislature for human genetic resources.
Patents Act No. 57 of 1978
In 2005, section 2 of the Patents Act No. 57 of 1978[18] was amended 
to include certain definitions as well as the requirement for an 
applicant of a patent to furnish information relating to any role 
played by an indigenous biological or genetic resource or traditional 
knowledge. Those who wish to file an application to the Patents 
Office using indigenous knowledge are obligated to disclose their 
source, therefore creating space to work out an equitable and fair 
compensation mechanism to the relevant community.
Section 25(1) of the Act states that a patent is granted for any new 
invention which involves an inventive step, and is capable of being 
used or applied in trade, industry or agriculture. For human genetic 
material patents, the definition itself poses major challenges.
‘Patent is granted for any new invention’
A specific gene sequence or partial thereof is not novel. Such sequence 
data has existed prior to its scientific investigation and takes into account 
the Supreme Court ruling in Myraid Genetics[19]that DNA isolated in its 
natural form cannot be patented or classified as a ‘new invention’.  
‘Which involves an inventive step’
This statement implies that something new was created or an inventive 
step arose out of a process. For genetic information such as targeted gene 
isolation and expression, it is difficult to prove; as such biological processes 
already occur in nature, whether they are ancestral or mutant. In addition 
research that finds evidence of a gene or other genomic data that is or 
could be linked to a specific disease or disorder, constitutes more an event 
of discovery rather than an invention. Furthermore, the scientific theory 
applied to such a discovery is not eligible for patenting under the condition 
of an inventive step.[20] This is justified by the need for scientific research to 
be continuously validated through reproducibility and proven robustness 
of a technique in order to either support or disprove a scientific theory.
‘Being used in trade, industry or agriculture’
Trade can be taken to include all activities in society where services or com-
mo dities of any kind are exchanged for money or other goods of value.[19,22] 
If an invention is to be patented it must be capable of being utilised or 
used in trade, industry or agriculture. Generally, South African law excludes 
discoveries, scientific theories and any human or animal treatment method 
including surgery, therapy or diagnostics as patentable inventions.[19] 
‘Agriculture covers the science of farming, whether animals or crops, and 
in its broad sense also includes forestry, gardening and horticulture.’[21] The 
wide range that an invention can cover makes it difficult to conceive its lack 
of utility, that is, not capable of being used or applied in trade, industry or 
agriculture, except for medical methods of treatment that are specifically 
excluded in the Patents Act.  Section 25(1) of the Act[19] does not define 
what a patent is but rather only provides clarification of what it cannot be.
Legal conclusion
Overall, the Patents Act leaves one with a feeling that information 
pertaining to human biological resources (that are relevant to genetics and 
other human associated studies) are overlooked and, upon review, one may 
question the apparent general lack of regulation of such material. However, 
the amendment requiring disclosure of the use of indigenous knowledge is 
noteworthy as this provides for a means to ensure fair compensation to the 
relevant communities through various benefit-sharing mechanisms. The 
question of ownership of human biological material undoubtedly raises 
the need for re-evaluation of how the concept of property is understood, 
interpreted and defined with regard to human genetic material. This in 
turn, should provide a link between open source data and biotechnology, 
as well as genomics as a whole with humanitarian objectives. Therefore, 
the potential to re-negotiate and re-design biotechnology with regard to 
human genetic material and information does exist.
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